Anti-NKG2A Monoclonal Antibody Sym025 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Anti-NKG2A Monoclonal Antibody Sym025 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- S095029
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Servier Bio-Innovation LLC (2) · Institut de Recherches Internationales Servier (1)
Often tested with
Tested in the same studies.
SYM-023 (1) · Anti-CD73 Monoclonal Antibody S095024 (1) · SYM-021 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-NKG2A Monoclonal Antibody Sym025.
- Apr 2027Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/2 · Servier Bio-Innovation LLC
- Aug 2027A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Phase 1/2 · Servier Bio-Innovation LLC
Studies
Open first, then newest update. How each study uses Anti-NKG2A Monoclonal Antibody Sym025 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 1/2Servier Bio-Innovation LLCNCT06162572Written as S095029How we know
- S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal CancersCompletedPhase 1Institut de Recherches Internationales ServierNCT05162755Written as S095029How we know
- A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingPhase 1/2Servier Bio-Innovation LLCNCT06116136Written as S095029How we know